ClinicalTrials.gg
TerminatedNCT02623504Updated Mar 3, 2023

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

A Phase 4 interventional study of Carbamazepine and Placebo in Bipolar Disorder, sponsored by Validus Pharmaceuticals. Terminated at 4 sites in United States. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-03-03.

Sponsored by Validus Pharmaceuticals · Phase 4, Interventional, and Treatment

Why this study was terminated
No apparent therapeutic effects that was superior to placebo

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 837 studies in Bipolar Disorder with a site in United States — 77 open to participants now, 96 under way, 8 of them phase 3. Bipolar Disorder · United States.

Enrollment
584th of 704
17 · median 58
Started
2016
with 28 others
Phase 4
155 of 837
8 open now
Registered
553rd of 837
by date

Among the 837 studies in Bipolar Disorder with a site in United States, this one is the 584th largest by enrollment of the 704 interventional ones that give a count, is one of 29 that started in 2016, is one of 155 in phase 4, and was the 553rd registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

77 of the 837 studies in Bipolar Disorder with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 837 studies in Bipolar Disorder with a site in United States, or all of them as a file.
02

Study summary

A phase 4 unequal randomization, double blind study to evaluate the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an Open label and long term maintenance treatment in children and adolescents aged 10-17 years diagnosed with acute manic or mixed Bipolar I Disorder

Read the detailed description

The primary objective of this study is to evaluate under double blind conditions the dose tolerance and safety of extended release Equetro (carbamazepine) versus placebo followed by an open label and long term maintenance treatment on extended release Equetro in children and adolescents aged 10-17 year diagnosed with acute manic or mixed bipolar I disorder. The safety evaluations will be based on the occurrence of treatment-emergent adverse events, laboratory values, physical examination, vital signs ECG and trough serum level of study medication. The secondary objective is to evaluate under double blind conditions the efficacy of extended release Equetro versus placebo followed by an open label and long term maintenance treatment on extended release Equetro in children and Adolescents Aged 10-17 years diagnosed with acute manic or mixed Bipolar I disorder. Efficacy evaluations will be based on the measures of YMRS, CGI-S, CGI-I, CDRS-R. Manic episodes over double blind and open label periods will comprise the use of study medication and duration of night time sleep as monitored using a daily diary. Subject's will be enrolled in the double blind period for two months and evaluated on a weekly basis. Once completing the db phase they will continue on Equetro for long term maintenance for an additional six months. Placebo subject will have the opportunity to continue for another eight months in the study. The first two months will be the titration period as was done in the db phase and then they will have the option to continue in the study for an open long term maintenance for and additional 6 months. During the maintenance period subjects will be evaluated for safety and efficacy on a monthly basis. At the end of the study there will be a 30 day follow-up.

03

Conditions studied

  • Bipolar Disorder

Browse trials for

Keywords

  • Carbamazepine
  • Equetro
  • Bipolar I Disorder
  • Bipolar I Disorder in Children
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written, signed and dated from subject, parents or legal guardians.
  • Subject must be willing to participate for the duration of the study (8-10 months)
  • Subject must meet criteria for a primary diagnosis of bipolar I disorder.
  • MINI KID administered and ruled out other psychiatric diagnosis.
  • ADHD Rating Scale-IV is ruled negative.
  • YMRS Score 20 or greater
  • CGI-S score of 4 or greater
  • CGI-I Global Evaluation score of 4 or less
  • Must be aged between 10 and 17 years
  • Male and non-pregnant, non-lactating females who agree to comply with requirements
  • Functioning at an age appropriate level intellectually as deemed by the Investigator
  • Subject has no co-morbid conditions that would affect efficacy, safety or tolerability or in any way interfere with the subject's participation in the study
  • Subject, parents and legal guardians are able to and willing to comply with study procedures and restrictions
  • Must have a satisfactory medical assessment with no abnormalities
  • Able to avoid grapefruit and grapefruit juice for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subject has a current controlled or uncontrolled co-morbid psychiatric that could interfere with clinical assessments or study conduct.
  • Naive subjects whose symptoms are being controlled on their prescribed medication(s) will not be eligible to participate.
  • History of lack of therapeutic response to an adequate trial of carbamazepine to treat bipolar I disorder
  • Believed by the Investigator to be acutely at risk for suicidal or violent behavior towards him/her or others, or a history of a suicide attempt requiring general medical intervention
  • Subject's bipolar diagnosis is believed secondary to traumatic injury or another general medical condition.
  • A history or known presence of cardiovascular, hepatic, hematological, immunological (including , gastro-intestinal or renal disease or any other unstable medical illness that could affect the action, absorption or disposition of the product, or clinical or laboratory assessments
  • A history of aplastic anemia, agranulocytosis or bone marrow depression
  • A history of seizure disorder, other than a single childhood febrile seizure\
  • A history of severe, unstable asthma
  • Currently hospitalized for the treatment of psychiatric symptoms.
  • Presence of any mental disorder due to a general medical condition
  • Presence of abnormal thyroid function that is not adequately treated in the opinion of the Investigator
  • Use of ECT, any investigational drug, CYP450 3A4 inhibitors, antidepressants, anxiolytics, sedative hypnotics, antipsychotics, mood stabilizers, ADHD medications, or clozapine in a specified time period prior to the initiation of the study
  • Use of any nutraceutical to include, but not limited to any over the counter herbal preparations e.g. Gingko Biloba, St John's Wort, Kava Kava and Ephedra.
  • Positive urine drug screen
  • History of alcohol or other substance abuse or dependence as defined by (except caffeine or nicotine) within the last 6months
  • Female subjects with a positive pregnancy test or who are pregnant, lactating, who are less than 6 months post partum, or who cannot be relied upon to use adequate
  • Subjects who have previously been enrolled in the Phase IV Multi-Center , Open-Label Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Acute Manic or Mixed Bipolar I Disorder and subsequently withdrawn
  • Subjects with a body weight of ≤65kg
  • Family of investigational site staff
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Equetro

    200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.

    Drug: Carbamazepine

  • Placebo comparator
    Placebo

    Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.

    Drug: Placebo

Interventions

  • 200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.

    Also known as: Equetro

  • DrugPlacebo

    Dosage to match active treatment by mouth twice daily in the morning and in the evening.

06

What researchers measure

Primary outcomes

  1. Dose tolerance and safety of Equetro based on occurrence of adverse events, lab values, physical exams, vital signs, ECG's, and trough serum levels of study medications

    Time frame: Duration of the study (8-10 months)

Secondary outcomes

  1. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured using the Young Mania Rating Score (YMRS)

    Time frame: Weekly during the double blind period (8 weeks), monthly during the maintenance period (6-8 months)

  2. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured using Clinical Global Impressions - Improvement and Severity (CGI-I, CGI-S)

    Time frame: Weekly during the double blind period (8 weeks), monthly during the maintenance period (6-8 months)

  3. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured using the Children's Depression Rating Scale - Revised (CDRS-R)

    Time frame: Weekly during the double blind period, monthly during the maintenance period

  4. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured by assessing the subject's manic episodes throughout the study period

    Time frame: Duration of the study (8-10 months)

  5. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured by assessing the subject's weekly use of study medication

    Time frame: Weekly for the duration of the study (8-10 months)

  6. Efficacy of Equetro in the treatment of children and adolescents aged 10-17 years with acute manic or mixed bipolar I disorder measured by assessing the duration of subject's nighttime sleep monitored using a diary or e-diary

    Time frame: Weekly for the duration of the study (8-10 months)

07

Study locations

4 sites
  • APG Research, LLC
    Orlando, Florida 32803, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • PsychCare Consultants
    Saint Louis, Missouri 63128, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2016 to primary completion in Nov 2018, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Dec 7, 2015
StartActual
Oct 24, 2016
Primary completionActual
Nov 1, 2018
CompletionActual
Nov 1, 2018
Last update
Mar 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02623504
Lead sponsor
Validus Pharmaceuticals
Responsible party
Sponsor
First posted
Dec 7, 2015
Start date
Oct 24, 2016
Primary completion
Nov 1, 2018
Completion
Nov 1, 2018
Last update
Mar 3, 2023

Study contacts

Robert Findling, MD
study director · John Hopkins - Kennedy Krieger Research
Lawrence Ginsberg, MD
principal investigator · Red Oak Psychiatry
Morteza Nadjafi, MD
principal investigator · APG Research
Mohd Azfar Malik, MD
principal investigator · Psych Care Consultants Research

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbamazepine

Start the discussion